Cancer Chemotherapy and Pharmacology

, Volume 65, Issue 3, pp 509–514 | Cite as

A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma

  • Frederick Locke
  • Joseph I. Clark
  • Thomas F. Gajewski
Original Article



Although much focus has been placed on immunotherapy for melanoma, further development of chemotherapy approaches is needed. Melanoma is responsive to platinum compounds and taxanes, but there is limited experience with combinations of these agents. Oxaliplatin has been reported to have detectable activity in melanoma, and a phase I study has identified a tolerable dose and schedule of oxaliplatin in combination with docetaxel and hematopoietic growth factor support. GM-CSF has a theoretical advantage of immune potentiation. These considerations supported the study of oxaliplatin, docetaxel, and GM-CSF in patients with advanced melanoma.


Eligibility included adequate organ function, PS ≤ 2, at most one prior chemotherapy and one prior immunotherapy, no prior treatment with oxaliplatin or taxanes and no chremophor allergy. After premedication, docetaxel was administered day 1 at 75 mg/m2, then oxaliplatin on day 2 at 85 mg/m2. GM-CSF (250 mcg/m2) was administered s.c. days 3–12. Cycles were 21 days in length, and disease reevaluation was performed every two cycles by RECIST criteria.


Nineteen patients received at least one cycle, eight with one prior systemic therapy, five with two prior systemic therapies. Five patients did not complete two cycles and were not formally evaluable for response. Five patients had stable disease (SD), including one who failed two prior therapies and went on to receive ten cycles. The remaining nine patients displayed progressive disease (PD) after two cycles. Notable toxicities included seven cases (37%) of grade III/IV neutropenia and two (11%) hypersensitivity reactions.


This combination of oxaliplatin, docetaxel, and GM-CSF has limited clinical activity in previously treated patients with advanced melanoma. Exploration in treatment-naïve patients may still be warranted.


Melanoma Metastatic Oxaliplatin Docetaxel GM-CSF Chemotherapy 


  1. 1.
    Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105–2116PubMedGoogle Scholar
  2. 2.
    Johnson RO, Metter G, Wilson W, Hill G, Krementz E (1976) Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group. Cancer Treat Rep 60:183–187PubMedGoogle Scholar
  3. 3.
    Patel PM (2008) Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV malignant melanoma final results of the randomized phase III study (EORTC 18032). In: 33rd congress of the European Society for Medical OncologyGoogle Scholar
  4. 4.
    Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, Einarson TR (2007) Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev 33:665–680CrossRefPubMedGoogle Scholar
  5. 5.
    Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM (2008) Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26:527–534CrossRefPubMedGoogle Scholar
  6. 6.
    Mortimer JE, Schulman S, MacDonald JS, Kopecky K, Goodman G (1990) High-dose cisplatin in disseminated melanoma: a comparison of two schedules. Cancer Chemother Pharmacol 25:373–376CrossRefPubMedGoogle Scholar
  7. 7.
    Legha SS, Ring S, Papadopoulos N, Plager C, Chawla S, Benjamin R (1989) A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 64:2024–2029CrossRefPubMedGoogle Scholar
  8. 8.
    Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745–2751PubMedGoogle Scholar
  9. 9.
    Mohammed MQ, Retsas S (2000) Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin. Anticancer Drugs 11:859–863CrossRefPubMedGoogle Scholar
  10. 10.
    Raymond E, Lawrence R, Izbicka E, Faivre S, Von Hoff DD (1998) Activity of oxaliplatin against human tumor colony-forming units. Clin Cancer Res 4:1021–1029PubMedGoogle Scholar
  11. 11.
    Mathe G, Kidani Y, Triana K, Brienza S, Ribaud P, Goldschmidt E, Ecstein E, Despax R, Musset M, Misset JL (1986) A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP). Biomed Pharmacother 40:372–376PubMedGoogle Scholar
  12. 12.
    Gogas H, Bafaloukos D, Bedikian AY (2004) The role of taxanes in the treatment of metastatic melanoma. Melanoma Res 14:415–420CrossRefPubMedGoogle Scholar
  13. 13.
    Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F (1991) Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51:4845–4852PubMedGoogle Scholar
  14. 14.
    Hanauske AR, Degen D, Hilsenbeck SG, Bissery MC, Von Hoff DD (1992) Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 3:121–124PubMedCrossRefGoogle Scholar
  15. 15.
    Dykes DJ, Bissery MC, Harrison SD Jr, Waud WR (1995) Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere). Invest New Drugs 13:1–11CrossRefPubMedGoogle Scholar
  16. 16.
    Einzig AI, Schuchter LM, Recio A, Coatsworth S, Rodriquez R, Wiernik PH (1996) Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy. Med Oncol 13:111–117CrossRefPubMedGoogle Scholar
  17. 17.
    Aamdal S, Wolff I, Kaplan S, Paridaens R, Kerger J, Schachter J, Wanders J, Franklin HR, Verweij J (1994) Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer 30A:1061–1064CrossRefPubMedGoogle Scholar
  18. 18.
    Bissery MC, Vrignaud P, Lavelle F (1995) Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination. Semin Oncol 22:3–16Google Scholar
  19. 19.
    Kouroussis C, Agelaki S, Mavroudis D, Kakolyris S, Androulakis N, Kalbakis K, Souglakos J, Mallas K, Bozionelou V, Pallis A, Adamtziki H, Georgoulias V (2003) A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer. Anticancer Res 23:785–791PubMedGoogle Scholar
  20. 20.
    Dranoff G (2002) GM-CSF-based cancer vaccines. Immunol Rev 188:147–154CrossRefPubMedGoogle Scholar
  21. 21.
    Spitler LE, Grossbard ML, Ernstoff MS, Silver G, Jacobs M, Hayes FA, Soong SJ (2000) Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 18:1614–1621PubMedGoogle Scholar
  22. 22.
    Nasi ML, Lieberman P, Busam KJ, Prieto V, Panageas KS, Lewis JJ, Houghton AN, Chapman PB (1999) Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells. Cytokines Cell Mol Ther 5:139–144PubMedGoogle Scholar
  23. 23.
    Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328–332CrossRefPubMedGoogle Scholar
  24. 24.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMedGoogle Scholar
  25. 25.
    Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10CrossRefPubMedGoogle Scholar
  26. 26.
    Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N (1998) Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16:1752–1759PubMedGoogle Scholar
  27. 27.
    Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS (2002) Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20:2045–2052CrossRefPubMedGoogle Scholar
  28. 28.
    Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle TM, Schmittel A, Schadendorf D, Velu T, Negrier S, Kleeberg U, Lehman F, Suciu S, Eggermont AM (2005) Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 23:6747–6755CrossRefPubMedGoogle Scholar
  29. 29.
    Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Seipp CA, Einhorn JH, White DE, Steinberg SM (1999) Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 17:968–975PubMedGoogle Scholar
  30. 30.
    Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM (2008) Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 26:5748–5754CrossRefPubMedGoogle Scholar
  31. 31.
    Schachter J, Rakowsky E, Sulkes A, Adler A (1998) A sequential four-drug chemotherapy and biotherapy with interferon alpha and GM-CSF—an innovative protocol for the treatment of metastatic melanoma. Cancer Biother Radiopharm 13:155–164CrossRefPubMedGoogle Scholar
  32. 32.
    Vaughan MM, Moore J, Riches PG, Johnston SR, A’Hern ME, Hill ME, Eisen T, Ayliffe MJ, Thomas JM, Gore ME (2000) GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma. Ann Oncol 11:1183–1189CrossRefPubMedGoogle Scholar
  33. 33.
    Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539–3543CrossRefPubMedGoogle Scholar
  34. 34.
    Chang AE, Li Q, Bishop DK, Normolle DP, Redman BD, Nickoloff BJ (2000) Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 11:839–850CrossRefPubMedGoogle Scholar
  35. 35.
    Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, Stuge TB, Groshen SG, Gee C, Jeffery GG, Sian S, Lee PP (2003) Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 97:186–200CrossRefPubMedGoogle Scholar
  36. 36.
    Aruga A, Tanigawa K, Aruga E, Yu H, Chang AE (1999) Enhanced adjuvant effect of granulocyte-macrophage colony-stimulating factor plus interleukin-12 compared with either alone in vaccine-induced tumor immunity. Cancer Gene Ther 6:89–95CrossRefPubMedGoogle Scholar
  37. 37.
    Gamelin L, Boisdron-Celle M, Delva R, Guerin-Meyer V, Ifrah N, Morel A, Gamelin E (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10:4055–4061CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Frederick Locke
    • 2
  • Joseph I. Clark
    • 3
  • Thomas F. Gajewski
    • 1
    • 2
  1. 1.Department of PathologyUniversity of ChicagoChicagoUSA
  2. 2.Department of MedicineUniversity of ChicagoChicagoUSA
  3. 3.Cardinal Bernardin Cancer Center, Department of MedicineLoyola University ChicagoMaywoodUSA

Personalised recommendations